IL22 and malignant colon neoplasm: Since the TH22-related cytokine IL-22 has been reported to promote tumorigenesis in distinct cancer entities, including lung, ovarian, breast, gastric, pancreatic, and colon cancers, the IL-22-IL-22R1 pathway has become an attractive target for anticancer therapy (154–156).